Tuesday - Goldman Sachs (NYSE:GS) initiated coverage on BrightSpring Health (NASDAQ:BTSG) with a Buy rating and a price target of $26.00. The firm highlighted the company's position as a scaled national healthcare services provider, emphasizing its focus on pharmacy services and patient-level care in home and community settings. Goldman Sachs pointed out the company's strong clinical and operational capabilities, which they believe will enable BrightSpring Health to capture market share and deliver consistent organic revenue growth.
The analysis by Goldman Sachs suggests that BrightSpring Health operates in markets that are expanding at a rate of 6.0 to 6.5% based on EBITDA, with the company expected to outpace this through a compound annual growth rate (CAGR) of approximately 7.7% through 2026. Additionally, the firm anticipates organic EBITDA growth of around 9.1%, with the potential for further increases stemming from strategic mergers and acquisitions.
Goldman Sachs forecasts that BrightSpring Health's EBITDA will follow an upward trajectory of about 11%, excluding Quality Incentive Program (QIP) headwinds. The firm also compares BrightSpring Health favorably to its competitors in terms of growth potential, despite a slight concern regarding the company's leverage, which is projected at 4.3 times for the year 2024.
The investment bank's valuation model applies an enterprise value to EBITDA (EV/EBITDA) multiple of approximately 13.3 times to BrightSpring Health's 2025 estimates. This calculation supports the 12-month price target of $26. In the view of Goldman Sachs, key factors that will contribute to narrowing the valuation gap and enhancing investment returns include robust growth, the emergence of medium-term upside drivers, successful mergers and acquisitions, and progress in reducing leverage.
InvestingPro Insights
As Goldman Sachs initiates coverage on BrightSpring Health with a bullish outlook, insights from InvestingPro provide additional context to the healthcare service provider's financial health and market performance. BrightSpring Health, with a market capitalization of $1.83 billion, is navigating through a challenging financial landscape. The company's Price to Earnings (P/E) ratio stands at -6.51, reflecting market sentiment towards its earnings potential. Moreover, the latest data for the last twelve months as of Q3 2023 shows an adjusted P/E ratio of -9.81, further emphasizing investor concerns regarding profitability.
Despite notable revenue growth of 11.53% over the last twelve months as of Q3 2023, InvestingPro Tips highlight significant challenges. The company is grappling with a significant debt burden and is not expected to be profitable this year, with net income projected to drop. Additionally, the stock's Relative Strength Index (RSI) suggests it is currently in overbought territory, which may concern potential investors considering entry points.
InvestingPro also points out that BrightSpring Health is trading near its 52-week low and does not pay a dividend to shareholders, which may influence the investment decisions of income-focused investors. For those seeking a deeper dive into BrightSpring Health's financials and market performance, InvestingPro offers additional tips. Interested readers can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking more valuable insights. Currently, there are 7 additional InvestingPro Tips available that could provide further clarity on the company's outlook.
It's important to note that while Goldman Sachs has a positive view of BrightSpring Health's growth potential and market positioning, the InvestingPro data and tips present a more nuanced picture that potential investors should consider. With the next earnings date on February 29, 2024, all eyes will be on BrightSpring Health's performance and strategic initiatives moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.